---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-035556"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:27:54.040609+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate

## Summary
- Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).
- Year-end cash $7.5M; subsequent ATM raised ~$4.5M.
- Ibezapolstat Phase 2b: 96% clinical cure (25/26), 100% sustained cure at 30 days.
- FDA End of Phase 2 meeting scheduled April 2024; Phase 3 plan to be discussed.
- EMA granted SME designation; additional microbiome data positive vs vancomycin.

## SEC filing metadata
- accession: 0001104659-24-035556
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/tm249120d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-035556
- JSON: https://secwatch.observer/filing/0001104659-24-035556.json
- Plain text: https://secwatch.observer/filing/0001104659-24-035556.txt

## Key facts
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income $5.1 million, EPS $0.37 per diluted share.
  - Period: the three months ended December 31, 2023
  - Net income: $5.1 million
  - EPS: $0.37 per diluted share
  - Result: reported results
  source text: The Company reported a net loss of $5.1 million or $0.37 per diluted share for the three months ended December 31, 2023 compared to a net loss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $14.6.
  - Period: the year ended December 31, 2023
  - Net income: $14.6
  - Result: reported results
  source text: oss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022, and a net loss of $14.6
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.